{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:12:31Z","timestamp":1791087151676,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T00:00:00Z","timestamp":1601856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.oret.2020.09.020","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T05:56:14Z","timestamp":1601358974000},"page":"519-527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":141,"title":["Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment"],"prefix":"10.1016","volume":"5","author":[{"given":"Caroline R.","family":"Baumal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Tanzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Seres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6982-9656","authenticated-orcid":false,"given":"Mayur R.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Feltgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2020.09.020_bib1","first-page":"4996","article-title":"Intraocular and systemic pharmacokinetics of brolucizumab (RTH258) in nonhuman primates.","volume":"57","author":"Nimz","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.oret.2020.09.020_bib2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"issue":"20","key":"10.1016\/j.oret.2020.09.020_bib3","article-title":"HAWK and HARRIER: 96-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","volume":"S0161-6420","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.020_bib4","series-title":"Beovu\u00ae [US prescribing information]","year":"2019"},{"key":"10.1016\/j.oret.2020.09.020_bib5","series-title":"Beovu\u00ae [Swissmedic prescribing information]","year":"2020"},{"key":"10.1016\/j.oret.2020.09.020_bib6","series-title":"Beovu\u00ae [prescription medicine decision summary]","year":"2020"},{"key":"10.1016\/j.oret.2020.09.020_bib7","series-title":"Beovu\u00ae[summary of product characteristics]","year":"2020"},{"key":"10.1016\/j.oret.2020.09.020_bib9","series-title":"Beovu\u00ae Kit for Intravitreal Injection 120 mg\/mL [Pharmaceuticals and Medical Devices Agency]","year":"2020"},{"key":"10.1016\/j.oret.2020.09.020_bib16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.020_bib17","doi-asserted-by":"crossref","first-page":"100680","DOI":"10.1016\/j.ajoc.2020.100680","article-title":"Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration","volume":"18","author":"Haug","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.oret.2020.09.020_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2005.10.052","article-title":"Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I\/II multicenter, controlled, multidose study","volume":"113","author":"Heier","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.020_bib19","doi-asserted-by":"crossref","first-page":"100687","DOI":"10.1016\/j.ajoc.2020.100687","article-title":"Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations","volume":"18","author":"Jain","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.oret.2020.09.020_bib20","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.ophtha.2020.03.035","article-title":"Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study","volume":"127","author":"Kunimoto","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.020_bib21","article-title":"Case report: combined central retinal artery and vein occlusion after anti-VEGF injection","author":"Rodriguez","year":"2017","journal-title":"Retina Today"},{"key":"10.1016\/j.oret.2020.09.020_bib22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/ICB.0b013e31823c4485","article-title":"Pseudovasculitis associated with vitreoretinal traction","volume":"6","author":"Tranos","year":"2012","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.oret.2020.09.020_bib23","article-title":"Occlusive retinal vasculitis following intravitreal brolucizumab","author":"Witkin","year":"2020","journal-title":"J\u00a0Vitreoretin Dis"},{"key":"10.1016\/j.oret.2020.09.020_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2020.2810","article-title":"Retinal vasculitis after administration of brolucizumab resulting in severe loss of visual acuity","author":"Kondapalli","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2020.09.020_bib25","series-title":"Lucentis\u00ae [US prescribing information]","year":"2006"},{"key":"10.1016\/j.oret.2020.09.020_bib27","doi-asserted-by":"crossref","first-page":"943409","DOI":"10.1155\/2013\/943409","article-title":"Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy","volume":"2013","author":"Agrawal","year":"2013","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.oret.2020.09.020_bib28","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/IAE.0000000000000398","article-title":"Frequency and characteristics of intraocular inflammation after aflibercept injection","volume":"35","author":"Fine","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.oret.2020.09.020_bib29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3341\/kjo.2015.29.5.325","article-title":"Sterile Inflammation after intravitreal injection of aflibercept in a Korean population","volume":"29","author":"Kim","year":"2015","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.oret.2020.09.020_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/09286586.2015.1122067","article-title":"Intraocular inflammation following intravitreal injection of anti-VEGF medications for neovascular age-related macular degeneration","volume":"23","author":"Knickelbein","year":"2016","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.oret.2020.09.020_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/0301-4738.58468","article-title":"Current approach in diagnosis and management of anterior uveitis","volume":"58","author":"Agrawal","year":"2010","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.oret.2020.09.020_bib32","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.ophtha.2014.03.006","article-title":"Objective measurement of vitreous inflammation using optical coherence tomography","volume":"121","author":"Keane","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.020_bib33","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/eye.2010.18","article-title":"Retinal vasculitis as an early sign of bacterial post-operative endophthalmitis","volume":"24","author":"Subbiah","year":"2010","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2020.09.020_bib34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ajo.2016.02.028","article-title":"Postinjection endophthalmitis rates and characteristics following intravitreal bevacizumab, ranibizumab, and aflibercept","volume":"165","author":"Rayess","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2020.09.020_bib35","first-page":"42","article-title":"Distinguishing between infectious endophthalmitis and noninfectious inflammation following intravitreal anti-VEGF Injection","volume":"3","author":"Schwartz","year":"2018","journal-title":"J\u00a0Vitreoretin Dis"},{"key":"10.1016\/j.oret.2020.09.020_bib36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/BOR.0000000000000271","article-title":"Retinal vasculitis","volume":"28","author":"Rosenbaum","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.oret.2020.09.020_bib37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/17469899.2019.1613153","article-title":"Diagnosing retinal vasculitis and its implications for treatment","volume":"14","author":"Abroug","year":"2019","journal-title":"Exp Rev Ophthalmol"},{"key":"10.1016\/j.oret.2020.09.020_bib38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.iio.0000155905.95303.1d","article-title":"Retinal vasculitis","volume":"45","author":"Levy-Clarke","year":"2005","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.oret.2020.09.020_bib39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40135-017-0135-2","article-title":"Central retinal artery occlusion: acute management and treatment","volume":"5","author":"Mehta","year":"2017","journal-title":"Curr Ophthalmol Rep"},{"key":"10.1016\/j.oret.2020.09.020_bib40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10792-009-9301-3","article-title":"A\u00a0clinical approach to the diagnosis of retinal vasculitis","volume":"30","author":"El-Asrar","year":"2010","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.oret.2020.09.020_bib41","doi-asserted-by":"crossref","first-page":"P259","DOI":"10.1016\/j.ophtha.2019.09.028","article-title":"Retinal and Ophthalmic Artery Occlusions Preferred Practice Pattern(R)","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.020_bib42","doi-asserted-by":"crossref","first-page":"OCT27","DOI":"10.1167\/iovs.15-19043","article-title":"Optical coherence tomography angiography","volume":"57","author":"Gao","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2020.09.020_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12348-019-0190-y","article-title":"Optical coherence tomography angiography in uveitis","volume":"9","author":"Tranos","year":"2019","journal-title":"J\u00a0Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.oret.2020.09.020_bib44","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4103\/0974-9233.58419","article-title":"Fluorescein and indocyanine green angiography for uveitis","volume":"16","author":"Herbort","year":"2009","journal-title":"Middle East Afr J Ophthalmol"},{"key":"10.1016\/j.oret.2020.09.020_bib45","article-title":"Brolucizumab-early real-world experience: BREW study","author":"Sharma","year":"2020","journal-title":"Eye (Lond)"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653020304000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653020304000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:29:17Z","timestamp":1762853357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653020304000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2468653020304000"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2020.09.020","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2020.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}